Neale Monks (pictured) has been appointed by Flexicon to take responsibility for its Northern UK territories. In his role as applications engineer, Monks will assist general sales manager Alan Walton in strengthening and improving Flexicon's UK market share of its process systems and equipment. Monks has worked in the past at Kemutec Powder Technologies and Hosokawa Micron.
Achim Kaufhold has joined Pharmexa as executive vice president, cso and chief medical officer (cmo). Kaufhold has spent more than 12 years in the biotech and pharmaceutical industry in senior management positions. Prior to starting up his own life science industry consultancy in 2006, Kaufhold was cmo and vice president of development at Chiron, now part of the Novartis group, as well as being a member of the executive committee of Chiron Vaccines.
Sigma-Aldrich has named Patrick Sullivan as vice president of r&d for its research biotech business unit. In this role, he will help to expand Sigma-Aldrich's leadership position through the development of new products for life science researchers. Sullivan has been involved with Sigma-Aldrich since 2005 as a member of its scientific advisory board, In his new role, Sullivan will report directly to David Smoller, president of research biotech.
Imperial College London has recently congratulated its deputy rector Professor Sir Leszek Borysiewicz on his appointment as the next chief executive of the UK's Medical Research Council. Borysiewicz has served at the university since February 2001, joining as principal of the faculty of Medicine from the University of Wales. In August 2004 he became deputy rector.
Amira Pharmaceuticals, a small molecule pharmaceutical company, has appointed Hari Kumar as its chief business officer. Kumar began his career at Roche, eventually progressing to Group Franchise Manager for the Transplant business. He then accepted an assignment to help the Japanese pharmaceutical company Eisai establish commercial operations in Europe. While at Eisai, Kumar participated in the launch of Aricept in Europe. He then returned to Roche, where he most recently served in a business development role.
Sebastien Quesney has joined Magnisense as technical development manager with worldwide responsibilities. The appointment reinforces Magnisense's management team, which aims to progress from a start-up to a fully-fledged company with real products. Quesney will be in charge of the development and production of Magnisense's MIAtek technology and will work with Magnisense's internal marketing and instrumentation teams and external partners involved in clinical trials or engineering.